Wikisage, the free encyclopedia of the second generation, is digital heritage
Fabry disease: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(1-deoxygalactonojirimycin) |
||
| Line 2: | Line 2: | ||
<gallery>File:Morbus Fabry affected organs.svg.png</gallery> | <gallery>File:Morbus Fabry affected organs.svg.png</gallery> | ||
[[migalastat]] received an orphan drug approval | [[migalastat]] or 1-deoxygalactonojirimycin received an orphan drug approval | ||
<ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM616598.htm</ref> | <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM616598.htm</ref> | ||
<references/> | <references/> | ||
Revision as of 00:39, 11 August 2018
Fabry disease is a genetic condition involving lysosomal storage (E75.2)[1]
migalastat or 1-deoxygalactonojirimycin received an orphan drug approval [2]